The Chinese influenza vaccines market is expected to record a value of nearly US$ 180 Million by the year-end of 2027 and Europe is anticipated to be the fastest-growing market during the forecast period
Dallas, United States - April 23, 2021 /MarketersMedia/ —
The research study on Influenza Vaccines 2021-2027 covers the COVID-19 impact analysis, growth drivers, size, share, and future outlook
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccines, the introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most of the countries.
The number of persons being vaccinated with influenza vaccines worldwide will touch the figure of 500 Million by the year-end of 2027
Request a pdf sample at https://www.orbisresearch.com/contacts/request-sample/5901384
Long–term Growth Projection:
The global influenza vaccines market size is set to surpass US$ 6.5 Billion by the year-end of 2021. Influenza vaccines demand is expected to increase in the forecast period. The United States influenza vaccines market is projected to grow with a significant CAGR in the forecast period. In Japan, the influenza vaccines market holds a rewarding growth opportunity for the future as the demand for the vaccine isgrowing significantly. The Chinese influenza vaccines market is expected to record a value of nearly US$ 180 Million by the year-end of 2027. Europe is anticipated to be the fastest-growing market during the forecast period. The United Kingdom and Germany are the leading revenue generators of the market. Emerging players backed by technological advancements are developing vaccines that offer a more realistic experience
The Report Provides a Comprehensive Analysis of Company Profiles Listed Below:
• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus (CSL Limited)
• AstraZeneca
• Mylan
• BioDiem
• Novavax
• Medicago
• Moderna Inc
• Pneumagen
• Daiichi–Sankyo
• Altimmune
• FluGen
• Imutex
• EpiVax
• Versatope Therapeutics, Inc.
• Gamma Vaccines Pty Ltd.
• BiondVax Pharmaceuticals Ltd.
• Hualan Biological Engineering Inc.
• Shanghai Institute of Biological Products Co., Ltd.
Browse the report at https://www.orbisresearch.com/reports/index/global-influenza-vaccines-market-2021-2027
The Report Answers Questions Such As:
• What is the current size of the global influenza vaccines market? How much will this market be worth from 2020 to 2027?
• How many persons being vaccinated with influenza vaccines globally during 2015 – 2027?
• Which country is expected to hold the highest market share in theglobal influenza vaccine market?
• What are the main drivers and restraints in the global influenza vaccines market?
• What are the major deals happenings in the global influenza vaccines market?
• Who are the top players and what are their activities, revenue, recent developments, and prospects?
• What are some of the most prominent influenza vaccines currently in development? What are their activities, phase, platform technology, and recent developments?
Direct purchase the report at https://www.orbisresearch.com/contact/purchase-single-user/5901384
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Email: Send Email
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A.
Phone: +1 (972)-362-8199; +91 895 659 5155
Website: https://www.orbisresearch.com/reports/index/global-influenza-vaccines-market-2021-2027
Source: MarketersMedia
Release ID: 89006758
